Hengrui Pharmaceuticals

Explore the latest insights on Hengrui Pharmaceuticals and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Hengrui Pharmaceuticals’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.Explore the latest insights on Hengrui Pharmaceuticals and its impact on China's pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Hengrui Pharmaceuticals's developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

FDA Approves Eli Lilly's Onswik – Once‑Weekly Basal Insulin for Adults With Type 2 Diabetes
CompanyDrug

FDA Approves Eli Lilly’s Onswik – Once‑Weekly Basal Insulin for Adults With Type 2 Diabetes

Eli Lilly and Company (NYSE: LLY) announced that the U.S. FDA has approved Onswik (insulin efsitora alfa‑gobe), a once‑weekly basal insulin indicated, along with diet and exercise, to control high…

AstraZeneca to Invest USD 2 Billion in Summit Therapeutics – Clinical Collaboration Anchored on Ivonescimab and Claudin 18.2 ADC Sone‑Ve

AstraZeneca to Invest USD 2 Billion in Summit Therapeutics – Clinical Collaboration Anchored on Ivonescimab and Claudin 18.2 ADC Sone‑Ve

AstraZeneca Submits FDA NDA for Orpathys–Tagrisso Combination – Targeting MET‑Altered NSCLC After EGFR TKI Failure

AstraZeneca Submits FDA NDA for Orpathys–Tagrisso Combination – Targeting MET‑Altered NSCLC After EGFR TKI Failure

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Jiangsu Hengrui Pharmaceuticals Wins NMPA Nod for SGLT-2 Inhibitor and Metformin Combo for Type 2 Diabetes

CompanyDrug

Jiangsu Hengrui Pharmaceuticals Advances Novel Cancer Therapies with NMPA Clinical Trial Approval

CompanyDrug

Jiangsu Hengrui Pharmaceuticals Secures NMPA Approval for Abiraterone in Prostate Cancer Treatment

CompanyDeals

Jiangsu Hengrui’s SHR-A2009 Earns Fast-Track Status for Metastatic NSCLC Treatment

Hospital

Hengrui Pharmaceuticals-Backed Nanjing Tianyinshan Hospital Opens as Class 3A Oncology Specialist Center

CompanyDrug

Lee’s Pharmaceutical’s Socazolimab Becomes China’s First PD-L1 mAb for Cervical Cancer

CompanyDrug

Jiangsu Hengrui Pharmaceuticals Wins NMPA Approvals for SLE and Lymphoma Drug Candidates

CompanyDrug

Jiangsu Hengrui Seeks NMPA Approval for Camrelizumab-Famitinib Combo in Cervical Cancer

Show More